Google’s biotech venture hit by ethical concerns over deal with luxury clinic
By Charles Piller,
STAT
| 04. 07. 2016
Untitled Document
MOUNTAIN VIEW, Calif. — Andrew Conrad, who runs Google’s ambitious biotech offshoot, successfully pushed the company to award a research contract to a luxury health clinic he largely owns that has no documented experience with this kind of work, STAT has learned. The arrangement has stirred concern inside Verily Life Sciences — and among corporate governance experts who see it as a conflict of interest.
Verily is also marketing to pharmaceutical companies a wealth of data on volunteers who participate in its major health study, called Baseline. It’s unclear whether Verily has informed volunteers of its plans to profit on their health data; the company declined to provide a copy of the consent agreement for volunteers tested at Conrad’s clinic.
Continue reading...
Image via Wikimedia
Related Articles
By Megan Molteni and Anil Oza, STAT | 10.07.2025
For two years, a panel of scientific experts, clinicians, and patient advocates had been hammering out ways to increase community engagement in National Institutes of Health-funded science. When they presented their road map to the NIH Director Jay Bhattacharya last...
Paula Amato & Shoukhrat Mitalipov
[OHSU News/Christine Torres Hicks]
On September 30th, a team of 21 scientists from Oregon Health & Science University (OHSU) published a significant paper in Nature Communications, with a scientifically accurate but, to many, somewhat abstruse headline:
Induction of experimental cell division to generate cells with reduced chromosome ploidy
The lead authors were Shoukhrat Mitalipov, recently described here as “a push-the-envelope biologist,” and his long-term colleague Paula Amato. (Recall that in July the pair had co-published with...
By Pam Belluck, The New York Times | 10.17.2025
Before dawn on a March morning, Doug Whitney walked into a medical center 2,000 miles from home, about to transform from a mild-mannered, bespectacled retiree into a superhuman research subject.
First, a doctor inserted a needle into his back to...
By Julia Black, MIT Technology Review | 10.16.2025
Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...
